Liminatus Pharma, Inc.
LIMN
$3.84
$0.205.35%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 3.07M | 3.40M | 2.97M | 2.25M | 1.74M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.07M | 3.80M | 2.97M | 2.25M | 2.09M |
| Operating Income | -4.07M | -3.80M | -2.97M | -2.25M | -2.09M |
| Income Before Tax | -12.52M | -11.00M | -10.21M | -2.27M | -1.05M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -12.52 | -11.00 | -10.21 | -2.27 | -1.05 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -12.52M | -11.00M | -10.21M | -2.27M | -1.05M |
| EBIT | -4.07M | -3.80M | -2.97M | -2.25M | -2.09M |
| EBITDA | -4.06M | -3.80M | -2.70M | -1.82M | -1.12M |
| EPS Basic | -21.46 | -19.76 | -19.14 | -4.72 | -3.07 |
| Normalized Basic EPS | -5.81 | -6.60 | -6.21 | -5.46 | -3.78 |
| EPS Diluted | -21.46 | -19.76 | -19.14 | -4.72 | -3.07 |
| Normalized Diluted EPS | -5.81 | -6.60 | -6.21 | -5.46 | -3.78 |
| Average Basic Shares Outstanding | 2.77M | 2.27M | 1.90M | 1.71M | 1.52M |
| Average Diluted Shares Outstanding | 2.77M | 2.27M | 1.90M | 1.71M | 1.52M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |